title: Human immunodeficiency virus-like particles with consensus envelopes elicited broader cell-mediated peripheral and mucosal immune responses than polyvalent and monovalent Env vaccines.
abstract: Envelope (Env) sequences from human immunodeficiency virus (HIV) strains can vary by 15-20% within a single clade and as much as 35% between clades. Previous AIDS vaccines based upon a single isolate often could not elicit protective immune responses against heterologous viral challenges. In order to address the vast sequence diversity in Env sequences, consensus sequences were constructed for clade B and clade C envelopes and delivered to the mouse lung mucosa on the surface of virus-like particles (VLP). Consensus sequences decrease the genetic difference between the vaccine strain and any given viral isolate. The elicited immune responses were compared to a mixture of VLPs with Envs from primary viral isolates. This polyvalent vaccine approach contains multiple, diverse Envs to increase the breadth of epitopes recognized by the immune response and thereby increase the potential number of primary isolates recognized. Both consensus and polyvalent clade B Env VLP vaccines elicited cell-mediated immune responses that recognized a broader number of clade B Env peptides than a control monovalent Env VLP vaccine in both the systemic and the mucosal immune compartments. All three clade C Env vaccine strategies elicited similar responses to clade C peptides. However, both the consensus B and C Env VLP vaccines were more effective at eliciting cross-reactive cellular immune responses to epitopes in other clades. This is the first study to directly compare the breadth of cell-mediated immune responses elicited by consensus and polyvalent Env vaccines.
authors.affiliation: Center for Vaccine Research, University of Pittsburgh, Pittsburgh, PA 15261, USA.
authors.forename: Sean P
authors.initials: SP
authors.lastname: McBurney
authors.forename: Ted M
authors.initials: TM
authors.lastname: Ross
mesh_terms: D016915:AIDS Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D000280:Administration, Inhalation; D000818:Animals; D016384:Consensus Sequence / Q000235:genetics / Q000276:immunology*; D003429:Cross Reactions; D005260:Female; D006678:HIV / Q000276:immunology*; D006801:Humans; D007111:Immunity, Cellular; D018928:Immunity, Mucosal; D051379:Mice; D008807:Mice, Inbred BALB C; D022721:Vaccines, Virosome / Q000235:genetics / Q000276:immunology; D054299:env Gene Products, Human Immunodeficiency Virus / Q000235:genetics / Q000276:immunology*
chemical_list: D016915:AIDS Vaccines; D022721:Vaccines, Virosome; D054299:env Gene Products, Human Immunodeficiency Virus